Oncology According to Mikhail Blagosklonny

In a world where cancer is becoming the order of the day, people are in need of scientists like Mikhail Blagosklonny. He is defying all odds to study cancer and the different treatments. Mikhail is a scientist who has been involved with the study of cancer and aging.

Education background

Mikhail graduated with his Doctor of Medicine in internal medicine from the First Pavlov State Medical University. He later pursued his Ph.D. in experimental medicine and cardiology from the same University.

Learn more: https://www.ncbi.nlm.nih.gov/pubmed/?term=blagosklonny

Career

In 2002, Mikhail was appointed the associate professor of the New York Medical College. Soon after, he took on a position at the Ordway Research Institute as the senior scientist. In 2009, Mikhail left the organization to become a professor at the Roswell Park Cancer Institute. He later resigned from the position.

Apart from imparting knowledge to young people, Mikhail is involved in different research related to cancer and aging. His research interests revolve around the cancer therapies that can protect the cells from damage. Mikhail also studies the mechanisms of aging and the anti-aging drugs.

Blagosklonny is the editor-in-chief of three different journals which include; oncotarget which is a peer-reviewed medical journal that publishes research related to oncology, Aging also a peer-reviewed scientific journal, and Cell Cycle a peer-review journal that publishes research related to cell biology. Mikhail serves as a member of the editorial board of Cell Death and Differentiation.

As a research scientist, Mikhail has published over 270 papers in various journals. In all his publications, he has quoted over 25,000 citations. This has given him an h-index (author-level index) of 83. Visit ResearchGate.Net to learn more about Mikhail’s latest work.

TOR Signaling

Among his notable work, TOR Signaling has been the most successful. Mikhail has developed a hypothesis that seeks to understand the role of TOR Signaling in Aging and also cancer. He has also looked into the role of rapamycin, a drug that promotes life extension. According to Mikhail, people die because of the age-related diseases, however, by using Rapamycin they can slow down the age-related diseases. Mikhail states that with the elimination of the external causes of death, the main cause of death will be the post-aging syndrome.

The TOR Signaling has played an important role in treating cancer. Mikhail Blagosklonny research indicates that the over-activation of the TOR Signaling can lead to the development of tumors. In some of the common types of cancer like breast prostate, lung, brain, bladder, and melanoma, the mTOR Signaling activity is deregulated. It is, therefore, prudent for the constitutive activation to be practiced.

Research on the Effects of TOR Signaling has been done in other areas including the Central Nervous System, brain function (although more research is required), Alzheimer’s disease, and Autism.

Mikhail is an advocate for the use of Rapamycin in the life extension. Mikhail is also involved in the study of molecular biology and cellular in clinical investigations. Mikhail is involved in the study of tumor suppressors, oncogenesis, cell cycle, drug resistance, selective protection, mitosis, and apoptosis.

Blagosklonny is the author of aging hyperfunction theory.

Leave a Reply

Your email address will not be published. Required fields are marked *